UDP 300
Alternative Names: UDP-300Latest Information Update: 10 Nov 2023
At a glance
- Originator Cyclarity Therapeutics
- Class Cyclodextrins; Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Substance-related disorders
Most Recent Events
- 22 Sep 2023 Cyclarity Therapeutics has patent protection for composition, before September 2023 (Cyclarity Therapeutics website, September 2023)
- 22 Sep 2023 Early research in Substance related disorders in Australia (unspecified route) before September 2023 (Cyclarity Therapeutics pipeline, September 2023)